Abstract
The c-erbB-2 protein is overexpressed in 7% of gastric cancer cases, suggesting that anti-c-erbB-2 antibody therapy (trastuzumab; Herceptin) could be used. We report here a 28-year-old woman with metastatic gastric cancer overexpressing c-erbB-2 (3 + strong membrane staining on immunohistochemistry) who was treated with trastuzumab in combination with chemotherapy. A complete response was obtained with a combination of trastuzumab and oxaliplatin and was maintained with trastuzumab alone for 18 months. The patient relapsed and chemotherapy (capecitabine, docetaxel) was combined with the anti-c-erbB-2 antibody. The patient survived for 4 years with metastatic disease controlled for 2 years by immunochemotherapy. We conclude that the combination of trastuzumab and chemotherapy is efficient in the treatment of metastatic gastric carcinoma with overexpression of the c-erbB-2 protein.
Article PDF
Similar content being viewed by others
References
DJ Slamon W Godolphin LA Jones JA Holt SG Wong DE Keith et al. (1989) ArticleTitleStudies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 707–12 Occurrence Handle2470152 Occurrence Handle1:STN:280:BiaB2c3hsVA%3D
K Sakai S Mori T Kawamoto S Taniguchi O Kobori Y Morioka et al. (1986) ArticleTitleExpression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas J Natl Cancer Inst 77 1047–52 Occurrence Handle3464796 Occurrence Handle1:CAS:528:DyaL28Xmt1ektbw%3D
T Takehana K Kunitomo K Kono F Kitahara H Iizuka Y Matsumoto et al. (2002) ArticleTitleStatus of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay Int J Cancer 98 833–7 Occurrence Handle10.1002/ijc.10257 Occurrence Handle11948459 Occurrence Handle1:CAS:528:DC%2BD38Xis1Ohtbw%3D
PM Ravdin GC Chamness (1995) ArticleTitleThe c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers — a review Gene 159 19–27 Occurrence Handle10.1016/0378-1119(94)00866-Q Occurrence Handle7607568 Occurrence Handle1:CAS:528:DyaK2MXmvFWru78%3D
H Allgayer R Babic KU Gruetzner A Tarabichi FW Schildberg MM Heiss (2000) ArticleTitleC-erbB-2 is of independant prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems J Clin Oncol 18 2201–9 Occurrence Handle10829039 Occurrence Handle1:STN:280:DC%2BD3c3ptFajtw%3D%3D
M Nakajima H Sawada Y Yamada A Watanabe M Tatsumi J Yamashita et al. (1999) ArticleTitleThe prognostic significance of amplification and overexpression of c-met and c-erbB-2 in human gastric carcinomas Cancer 85 1894–902 Occurrence Handle10223227 Occurrence Handle1:CAS:528:DyaK1MXjtVCqsro%3D
T Mizutani M Onda A Tokunaga N Yamanaka Y Sugisaki (1993) ArticleTitleRelationship of c-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer Cancer 72 2083–8 Occurrence Handle8397058 Occurrence Handle1:STN:280:ByyA1cnmtlc%3D
CL Vogel MA Cobleigh D Tripathy JC Gutheil LN Harris L Fehrenbacher et al. (2002) ArticleTitleEfficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 719–26 Occurrence Handle10.1200/JCO.20.3.719 Occurrence Handle11821453 Occurrence Handle1:CAS:528:DC%2BD38XhsVGmt7o%3D
M Tanner M Hollmen TT Juntilla AI Kapanen S Tommola Y Soini et al. (2005) ArticleTitleAmplification of Her-2 in gastric carcinoma: association with topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab Ann Oncol 16 273–8 Occurrence Handle10.1093/annonc/mdi064 Occurrence Handle15668283 Occurrence Handle1:STN:280:DC%2BD2M%2FjvFyhsg%3D%3D
C Louvet T Andre JM Tigaud E Gamelin JY Douillard R Brunet et al. (2002) ArticleTitlePhase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients J Clin Oncol 20 4543–8 Occurrence Handle12454110 Occurrence Handle1:CAS:528:DC%2BD38XovVeisLw%3D
TR Evans G Pentheroudakis J Paul A McInnes R Blackie N Raby et al. (2002) ArticleTitleA phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma Ann Oncol 13 1469–78 Occurrence Handle10.1093/annonc/mdf243 Occurrence Handle12196374 Occurrence Handle1:STN:280:DC%2BD38vpvV2mtA%3D%3D
DJ Slamon B Leyland-Jones S Shak H Fuchs V Paton A Bajamonde et al. (2001) ArticleTitleUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783–92 Occurrence Handle10.1056/NEJM200103153441101 Occurrence Handle11248153 Occurrence Handle1:CAS:528:DC%2BD3MXisVGktrc%3D
HJ Burstein I Kuter SM Campos RS Gelman L Tribou LM Parker et al. (2001) ArticleTitleClinical activity of trastuzumab and vinorelbine in women with Her2-overexpressing metastatic breast cancer J Clin Oncol 19 2722–30 Occurrence Handle11352965 Occurrence Handle1:CAS:528:DC%2BD3MXkt1Omu7k%3D
A Webb D Cunningham JH Scarffe P Harper A Norman JK Joffe et al. (1997) ArticleTitleRandomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer J Clin Oncol 15 1–7
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rebischung, C., Barnoud, R., Stéfani, L. et al. The effectiveness of trastuzumab (Herceptin) combined with chemotherapy for gastric carcinoma with overexpression of the c-erbB-2 protein. Gastric Cancer 8, 249–252 (2005). https://doi.org/10.1007/s10120-005-0342-7
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10120-005-0342-7